Search Results
Your search for ASCO matches 21875 pages
Showing 18251 - 18300Ongoing NCI-Funded Clinical Trials Actively Recruiting Patients With Advanced Cancer
This issue of The ASCO Post launches a Clinical Trials Resource Guide to increase awareness of NCI-funded phase I, II, and III clinical studies for your patients with advanced cancer. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov. The clinical...
ESMO Releases Position Paper on Med-Oncs' Role in Cancer Care
A new position statement from the European Society for Medical Oncology (ESMO) reports that medical oncologists have a vital role to play in cancer care.1 According to the position statement, medical oncologists are specialist cancer physicians trained to provide treatment with drugs, spanning from ...
Cautious Comments on the TARGIT-A Trial
Numerous randomized trials have demonstrated that whole-breast irradiation plays an important role after breast-conserving surgery for invasive breast cancer. A recent meta-analysis of these trials indicated that whole-breast irradiation decreased the risk of total breast cancer relapse events and...
American Lung Association Applauds U.S. Preventive Services Task Force Recommendation of Screening for Those at High Risk of Lung Cancer
The American Lung Association issued the following statement on December 31, 2013, in response to the recommendation of the U.S. Preventive Services Task Force (USPSTF) to screen individuals at high risk of lung cancer. “The [USPSTF] made a recommendation that will save lives. The Task Force...
Molecularly Targeted Therapy for Lung Cancer
INSIDE THE BLACK BOX is an occasional column offering insight into the FDA and its policies and procedures. This installment addresses a changing paradigm in the treatment of lung cancer, exemplified by concurrent approval of a companion diagnostic with each of several new targeted agents or new...
IFM 2005-02 Update Differs From CALGB 100104: Why?
The updated analysis of the Intergroupe Francophone du Myelome (IFM) 2005-02 trial in newly diagnosed multiple myeloma patients showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival, according to...
Tivozanib Improves Progression-Free but Not Overall Survival vs Sorafenib in Metastatic Renal Cell Carcinoma
The investigational agent tivozanib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3. In a phase III trial reported in the Journal of Clinical Oncology by Robert J. Motzer, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC), and...
Genetic Flaw That Drives Some Ovarian Cancers Identified
Researchers at Dana-Farber Cancer Institute, Boston, have identified an overactive gene that drives about one-third of high-grade serous ovarian tumors—the most common and malignant type of ovarian cancer. The gene, GAB2, isn’t mutated or abnormal, but triggers cancerous cell growth because the...
Expert Point of View: Debu Tripathy, MD
Debu Tripathy, MD, Professor of Medicine, Co-Leader of the Women’s Cancer Program, and the Priscilla and Art Ulene Chair in Women’s Cancer at the University of Southern California Norris Cancer Center, Los Angeles, commented on the APT study for The ASCO Post. “In treating early-stage...
HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen
There may be a benefit for treating small HER2-positive tumors—a breast cancer subset for whom treatment recommendations have not been established but for whom there is still risk of recurrence—and this can be done with little toxicity, according to a multicenter study presented at the 2013 San...
Seven Studies at SABCS Make Dr. Jame Abraham's List of 'Practice-Changing' Talks
From December 10 to 14, the American Association for Cancer Research, the Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine once again hosted the San Antonio Breast Cancer Symposium (SABCS), presenting...
Philips Receives FDA Clearance for Spectral Breast Density Measurement Application
Royal Philips has announced that that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Spectral Breast Density Management Application for its MicroDose SI full-field digital mammography system. The application is the first spectral breast density measurement ...
International Society of Geriatric Oncology Meeting Explores Multidisciplinary, Tailored Treatment of Older Patients With Cancer
The annual meeting of the International Society of Geriatric Oncology (SIOG, www.siog.org) was held in Copenhagen from October 24 to 26. The theme of the meeting was the “Multidisciplinary Approach Towards Personalized Treatments.” The Society, which was founded in 2000, is a multidisciplinary...
ASCO's 50th Anniversary and the Road Ahead
As the American Society of Clinical Oncology celebrates its 50th anniversary, ASCO’s Chief Executive Officer Allen S. Lichter, MD, FASCO, recently talked with The ASCO Post about the Society’s past, present, and future. Important Milestone What are your thoughts about ASCO’s origins and its 50th...
Artemis Project® for a Preventive Breast Cancer Vaccine
I read with interest the article, “Breast Cancer Vaccines for Primary Prevention Move Toward Clinical Use,” which appeared in the December 15th issue of The ASCO Post (page 28). However, information presented regarding the National Breast Cancer Coalition’s (NBCC’s) Artemis Project for a breast...
Oncology Meetings
FEBRUARY 25th International Congress on Anti-Cancer TreatmentFebruary 4-6 • Paris, FranceFor more information: www.icact.fr APOS 11th Annual ConferenceFebruary 13-15 • Tampa, FloridaFor more information:www.apos-society.org/apos2014/ European Society for Medical Oncology Sarcoma and GIST...
Champions Oncology Names Chief Medical Officer
Champions Oncology, a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, has announced the appointment of Angela Davies, MD, as Chief Medical Officer. Dr. Davies has demonstrated experience in both academic...
Texas Children’s Hospital Announces New Chief of Interventional Radiology
The Department of Pediatric Radiology at Texas Children’s Hospital recently announced that Kamlesh U. Kukreja, MD, has been named the new Chief of Interventional Radiology. Dr. Kukreja has also been appointed as Assistant Professor of Radiology at Baylor College of Medicine. “For more than a...
Expect Questions, and Some Reluctance, About Getting a Flu Shot
People with weakened immune systems due to diseases like cancer are at increased risk of severe complications from the flu virus and should get flu shots annually. The Centers for Disease Control and Prevention (CDC) strongly encourages this practice, and most oncologists would recommend that for...
Cancer Patients Are at Increased Risk of Complications From the Flu and Should Receive Flu Shots, but Not the Nasal Spray
Widespread influenza activity continues to be reported by the Centers for Disease Control and Prevention (CDC), with a recent increase in flu-related hospitalizations.1,2 Patients with cancer are at increased risk from flu complications and should receive the flu shot, but not the flu nasal spray...
Grant to Develop Website and Mobile App to Track Radiation Therapy Toxicity Awarded to Radiation Oncology Resident
The Radiation Oncology Institute has selected Malolan S. Rajagopalan, MD, a radiation oncology resident at the University of Pittsburgh Cancer Institute, to receive a $20,000 grant for a project to compile best practices regarding the management of radiation therapy toxicity. Dr. Rajagopalan’s...
An Overview of the REGAL Trial and Anti-VEGF Therapies in Recurrent Glioblastoma
As published in the Journal of Clinical Oncology by Batchelor and colleagues1 and reviewed in a recent issue of The ASCO Post (November 15, 2013, page 106), the REGAL trial was a randomized, phase III, placebo-controlled, partially blinded trial evaluating the efficacy of cediranib, an...
Major Cancer Milestones in History, From ASCO’s CancerProgress.Net
To help tell the story of progress against cancer, ASCO launched CancerProgress.Net in 2011. The site is intended as a resource for media, policymakers, oncologists, advocates, and the public. One central feature of the site is an interactive timeline of major milestones in cancer treatment,...
Gary Lyman, MD, Joins Scott Ramsey, MD, PhD, in Co-Leading Hutchinson Institute for Cancer Outcomes Research at Fred Hutchinson
The Hutchinson Institute for Cancer Outcomes Research (HICOR) has named Gary Lyman, MD, MPH, the Institute’s Co-Director with Scott Ramsey, MD, PhD, an internist and health-care economist, and a member of the Cancer Prevention Program in the Public Health Sciences Division at Fred Hutchinson Cancer ...
Reports From the IPOS/AORTIC Travel Scholars
Eight individuals were awarded travel scholarships allowing them to attend the IPOS/AORTIC Program (International Psycho-Oncology Society/African Organization for Research and Training in Cancer) and share their experiences and efforts toward improving the psychosocial care of patients with cancer...
Surgeon General’s New Report Attributes Smoking as Cause of Death in More Than 20 Million Americans Over Past 50 Years
According to a new Surgeon General’s report issued last month, more than 20 million Americans have died from smoking over the past 50 years. The new report concludes that cigarette smoking kills nearly half a million Americans a year, with an additional 16 million suffering from smoking-related...
50th Anniversary of the First U.S. Surgeon General’s Report on Smoking and Health
“When the first Surgeon General’s Report was released in 1964, more than half of American men and over a third of women smoked and lung cancer had gone from an obscure disease to a leading cause of death. In issuing this pioneering report summarizing the known health risks of smoking, our nation’s...
Health IT Safety Guide
A new set of guides and interactive tools to help health-care providers more safely use electronic health information technology products, such as electronic health records (EHRs), are now available at www.HealthIT.gov. The Office of the National Coordinator for Health Information Technology (ONC)...
FDA Approves Combination Therapy for Unresectable or Metastatic Melanoma With BRAF V600E/K Mutations
The U.S. Food and Drug Administration (FDA) has approved trametinib (Mekinist) for use in combination with dabrafenib (Tafinlar) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutations. These mutations must be detected by an FDA-approved...
Dabrafenib Receives FDA Breakthrough Therapy Designation for BRAF-Mutated NSCLC
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for dabrafenib (Tafinlar) for the treatment of patients with metastatic BRAF V600E mutation–positive non–small cell lung cancer (NSCLC) who have received at least one prior line of platinum-containing...
ASCO Proposes New Framework for Medicare Reimbursement
In the fifth installment of the Physician Payment Reform Educational Series, ASCO presents an alternative for oncology reimbursement that recognizes and rewards high-quality, high-value care for patients with cancer. ASCO hopes this proposal will spark conversation within the oncology community and ...
Nearly 40 Practices Receive QOPI® Recertification for High-Quality Cancer Care
Nearly 40 practices have achieved certification through the Quality Oncology Practice Initiative (QOPI®) Certification Program (QCP™) for a second 3-year term. The QOPI Certification Program began certifying practices in 2010 and is now seeing the first wave of practices applying for a second term. ...
Cancer.Net’s Newest Resource—the Cancer.Net Blog
Starting this year, Cancer.Net added a new interactive blog to its list of resources. Using the blog, Cancer.Net will be able to share information in a more timely manner and respond to current events, including breaking news about cancer advances and other topics important to people affected by...
ASCO Cosponsors Inaugural Palliative Care in Oncology Symposium
In October, ASCO will cosponsor the inaugural Palliative Care in Oncology Symposium with the American Academy of Hospice and Palliative Medicine (AAHPM), the American Society for Radiation Oncology (ASTRO), and the Multinational Association of Supportive Care in Cancer (MASCC). The Symposium is...
Conquer Cancer Foundation Funds Research in Low- and Middle-Income Countries for the First Time
The Conquer Cancer Foundation of the American Society of Clinical Oncology has announced the four recipients of the inaugural 2014 International Innovation Grant, which is a new program that underscores the Foundation’s continued commitment to improving the care of patients worldwide. The 1-year...
ASCO Member Helps to Strengthen Cancer Care Internationally Through Philanthropy and Volunteer Service
Ian F. Tannock, MD, PhD, DSc, FASCO, Professor of Medical Oncology at Princess Margaret Hospital and University of Toronto, has long been an advocate for ASCO as a truly global society and a leader in cancer care worldwide. It’s something he encouraged during his time on ASCO’s Board of Directors,...
IPOS/AORTIC Conference Aims to Bring Comprehensive Care to Patients in Africa
More than 1,000 scientists from 66 countries, including 32 of the 52 African countries, attended the African Organization for Research and Training in Cancer (AORTIC) 9th International Conference on Cancer in Africa, held this past November in Durban, South Africa. The theme of the 2013 meeting was ...
ASCO President Issues Statement on Major Decline in Lung Cancer
Editor’s note: The Centers for Disease Control and Prevention (CDC) recently issued a report on lung cancer incidence trends in the United States.1 According to the report, incidence rates for lung cancer have decreased between 2005 and 2009, the period evaluated. Lung cancer incidence has...
Expert Point of View: Matthew Ellis, MB, PhD
Matthew Ellis, MB, PhD, Professor of Medicine and the Anheuser-Busch Chair in Medical Oncology at Washington University School of Medicine, St. Louis, commented for The ASCO Post on the emerging field of research on drugging PI3K mutations. Critical Mechanisms “Multiple somatic lesions in breast...
Lung Cancer Screening Facts
The U.S. Preventive Services Task Force has posted a supplemental fact sheet for clinicians on its final recommendation statement on screening for lung cancer.1 This resource is meant to help health-care professionals talk about lung cancer screening with their patients and determine if screening...
Expert Point of View: Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz, MD, PhD, Chair of the Non-Hodgkin Lymphoma Guideline Panel of the National Comprehensive Cancer Network (NCCN) and former Chief of the Lymphoma Service at Memorial Sloan-Kettering Cancer Center, New York, commented on the study by Yamshon et al for The ASCO Post. He said the...
Cancer Genes, Promiscuity, and the National Debt
There is no doubt that this is a halcyon period in oncology. The unraveling of the genome has been tremendously important, and finally has helped us to move treatment selection from an era of rational empiricism to one of refined, molecular prognostication. In the care of breast cancer, the impact...
Major Cancer Advances in 2013 Highlight Importance of Federal Funding
About one-third of the most important clinical advances in cancer last year were made possible at least in part through federal funding, according to ASCO’s annual report on progress in cancer, published in the Journal of Clinical Oncology.1 Significant Declines in Funding The report, “Clinical...
Addition of Carboplatin to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Supported by SABCS Studies
The achievement of a pathologic complete response in patients with triple-negative breast cancer was boosted by the addition of carboplatin to a standard neoadjuvant chemotherapy regimen, and by the addition of veliparib, an investigational oral PARP inhibitor, plus carboplatin to a standard...
Corrections to Note
In the January 15, 2014, issue of The ASCO Post, three errors occurred. These errors have since been corrected and revised versions of the articles may be viewed online at ASCOPost.com or via the QR code here. The errors were as follows below. Trastuzumab Dosing In the article “HER2-Positive...
Donald L. Morton, MD, an Icon in Surgical Oncology, Dies
“Tomorrow is the most important thing in life. Comes into us at midnight very clean. It’s perfect when it arrives and it puts itself in our hands. It hopes we’ve learned something from yesterday.” —John Wayne Donald L. Morton, MD, transformed the management of melanoma and breast cancer by...
Anticipated Shortage of Oncologists Will Strain Ability to Provide Quality Cancer Care
An update of the ASCO 2007 oncology workforce study found that the Patient Protection and Affordable Care Act, when fully implemented, may “modestly exacerbate” anticipated workforce shortages, increasing the demand for oncologists and radiation oncologists by 500,000 visits per year. “Unless...
Expect Questions from Patients
Like all early detection strategies, screening mammography involves trade-offs,” H. Gilbert Welch, MD, MPH, and Honor J. Passow, PhD, of the Dartmouth Institute for Health Policy & Clinical Practice, Hanover, New Hampshire, wrote in a Special Communication in JAMA Internal Medicine.1 They...
Confronting Uncertainty About the Harms and Benefits of Screening Mammography
“If women are to truly participate in the decision of whether or not to be screened [for breast cancer using mammography], they need some quantification of its benefits and harms,” asserted H. Gilbert Welch, MD, MPH, Professor of Medicine, and Honor J. Passow, PhD, Instructor, at The Dartmouth...
UN Agency Issues World Cancer Report 2014
A new global cancer report1 compiled by the United Nations’ International Agency for Research on Cancer (IARC) shows, as a single entity cancer is the biggest cause of mortality worldwide, and there were an estimated 8.2 million deaths from cancer in 2012. The report also noted that global cancer...
